Person:
BÜYÜKPINARBAŞILI, NUR

Profile Picture

Status

Kurumdan Ayrılmıştır

Email Address

Birth Date

Name

Job Title

First Name

NUR

Last Name

BÜYÜKPINARBAŞILI

Organizational Units

OrgUnit Logo
Organizational Unit

Filters

2015 - 20162
Reset filters

Settings

Author: Buyukpinarbasili, NURAuthor: Ersoy, YELİZ EMİNEItem Type: PublicationStart date: 2012End date: 2017

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    p53 expression and relationship with MDM2 amplification in breast carcinomas
    (2016-04-01) Buyukpinarbasili, NUR; Gucin, ZÜHAL; Ersoy, YELİZ EMİNE; ILBAK, Ayca; Kadioglu, HÜSEYİN; Muslumanoglu, Mahmut; BÜYÜKPINARBAŞILI, NUR; GÜCİN, ZÜHAL; ERSOY, YELIZ EMINE; KADIOĞLU, HÜSEYİN
    Carcinoma of the breast, like other malignancies, is a genetic disease with multiple genetic events leading to the malignant phenotype. p53 mutations are the most common genetic events in human cancer. Inactivation of p53 can be a result of mutation in gene sequence. One of the main structures that regulate p53 stabilization is MDM2. It suppresses p53 transcriptional activation by recognizing transactivation domain of p53. The loss of MDM2 function on p53 regulation results in deprivation of p53 tumor suppressor ability. Single nucleotide polymorphisms (SNP309 T->G exchange) or MDM2 amplification has been proposed to play a role in this issue. In the present study, our aim is to analyze p53 and MDM2 status and investigate their interactions in human sporadic breast carcinoma. The study groups were separated according to their molecular classifications. In each group, histologic type of the tumor, conventional prognostic parameters, p53, and MDM2 interactions were compared statistically. Tumors are divided into 4 subtypes due to estrogen and progesterone receptor status, HER-2, and Ki-67 proliferation index results. According to this classification, 23 cases are in the luminal A, 32 cases are in the luminal B, 15 cases are in the HER-2 positive, and 22 cases are in the triple-negative group, with a total of 92 cases. p53 expression is low in luminal breast carcinomas than HER-2 and triple-negative subtypes. MDM2 amplification frequency was found to be 5.4% in total. MDM2 gene amplification does not have a significant role in breast carcinogenesis, but other possible mechanisms may play a role in its inactivation. (C) 2016 Elsevier Inc. All rights reserved.
  • Thumbnail Image
    PublicationOpen Access
    Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest
    (2015-08-01) Gucin, ZÜHAL; GECER, Melin Ozgun; Buyukpinarbasili, NUR; SONMEZ, Cavide; Ersoy, YELİZ EMİNE; MUSLUMANOGLU, Mahmut; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; ERSOY, YELIZ EMINE
    Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas. Methods: Therefore, 146 breast carcinomas comprising 87 ER+/PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status. Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/ PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant. Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy.